Q-omics provides the consensus-scored TMEM183AP1 profile across patient tissues and cancer cell-line models. TMEM183AP1 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TMEM183AP1 is differentially expressed in 2, with the highest sampling consensus in HNSC. Additionally, TMEM183AP1 RNA expression shows 8,097 significant gene co-expression associations, with the highest sampling consensus in LIHC. Together, these results highlight KIRP, HNSC, and LIHC as cancer lineages where TMEM183AP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM183AP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM183AP1 survival associations across molecular data types. TMEM183AP1 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM183AP1 RNA expression–survival associations across cancer types. High TMEM183AP1 expression shows unfavorable associations in KIRP, ACC, THYM, KIRC, LUSC and LIHC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for TMEM183AP1 RNA expression.
This table summarizes TMEM183AP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM183AP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM183AP1 shows higher tumor expression in HNSC and KIRP. The HNSC box plot shows higher TMEM183AP1 RNA expression in tumor versus normal tissue (log2 FC = +0.046, t-test p = .016).
This table shows molecular features associated with TMEM183AP1 in patient tissues and cancer cell lines. In patient samples, TMEM183AP1 shows the broadest associations at the RNA and protein expression levels, with LIHC recurring as the lineage with the largest associated feature set.
